A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14%
A sustained run in the biotech’s stock price meets a complex fundamental picture.
An eight-day run in Kymera Therapeutics (KYMR) stock has added about $1.4 billion to the company’s market value. The stock has now moved higher for 8 consecutive trading days, delivering a cumulative gain of 14% over the period.
For investors holding the shares, this has been a significant move, bringing the company’s market capitalization to about $11 billion.
How The Streak Stacks Up Against The S&P 500
Here is how KYMR stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | KYMR | S&P 500 |
|---|---|---|
| 1D | 0.3% | 0.7% |
| 8D (Current Streak) | 14.1% | 2.6% |
| 1M (21D) | 0.3% | 3.0% |
| 3M (63D) | 33.7% | 4.8% |
| YTD 2026 | 47.1% | 13.9% |
| 2025 | 93.4% | 16.4% |
| 2024 | 58.0% | 23.3% |
| 2023 | 2.0% | 24.2% |
What does the data say about this run?
The market appears to be weighing rapid expansion against a lack of profitability. Kymera’s revenue over the last twelve months grew 134.8%, far outpacing the S&P 500 median revenue growth of 8.3%. However, its operating margin over the same period is -329.8%, compared to the S&P 500 median of 18.4%.
This move is specific to the stock; over the same 8 trading days the S&P 500 returned +2.6%. Such streaks are also not widespread, with just 2 S&P 500 stocks currently on winning streaks of 8 days or more.
How should I think about a streak like this?
A streak is a piece of information, not an instruction. It tells you that a stock has captured the market’s attention and has strong near-term momentum. The disciplined response is not to chase the trend or bet against it, but to use the new price as a prompt to re-evaluate the underlying business.
The numbers here provide a starting point for that work: weighing the company’s growth against its current losses and valuation.
A run like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Streaks End. Discipline Compounds
A run like this is genuinely useful information: something about this business has the market’s full attention. But streaks are where discipline gets tested, because the urge to chase strength is strongest right before it pauses.
The Trefis High Quality (HQ) Portfolio channels that urge into a system: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules rather than excitement. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Enjoy the streak; own the process.